Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1

Biochemistry

Volumn 48, Issue 26, 2009, Pages 6249-6258

  Crowley, Emily ^a   O'Mara, Megan L ^b,c   Reynolds, Catherine ^a   Tieleman, D Peter ^b   Storm, Janet ^a   Kerr, Ian D ^d   Callaghan, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATP HYDROLYSIS; ATP-ASE ACTIVITY; BASAL ACTIVITIES; CATALYTIC CYCLES; CLINICAL SETTINGS; CYSTEINE RESIDUES; DRUG BINDING; INTERDOMAIN COMMUNICATION; MULTIDRUG EFFLUX; NICARDIPINE; NUCLEOTIDE BINDING; P-GLYCOPROTEIN; TRANSMEMBRANE HELICES; UNDERLYING CAUSE; VINBLASTINE;

CELL MEMBRANES; CHEMOTHERAPY; GLYCOPROTEINS; HYDROLYSIS; NUCLEOTIDES;

DRUG INTERACTIONS;

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; NICARDIPINE; VINBLASTINE;

ARTICLE; BINDING KINETICS; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; BIOCATALYSIS; CYSTEINE; HUMANS; HYDROLYSIS; KINETICS; MODELS, MOLECULAR; NICARDIPINE; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; VINBLASTINE;

EID: 67650097355     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900373x     Document Type: Article

References (53)

1. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86, 695-698.
2. Pavelic, Z. P., Reising, J., Pavelic, L., Kelley, D. J., Stambrook, P. J., and Gluckman, J. L. (1993) Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch. Otolaryngol., Head Neck Surg. 119, 753-757. (Pubitemid 23198694)
3. Smit, J. J., Schinkel, A. H., Mol, C. A., Majoor, D., Mooi, W. J., Jongsma, A. P., Lincke, C. R., and Borst, P. (1994) Tissue distribution of the human MDR3 P-glycoprotein. Lab. Invest. 71, 638-649.
4. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., and Melamed, M. R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287.
5. Gottesman, M. M., Fojo, T., and Bates, S. E. (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
6. McDevitt, C. A., and Callaghan, R. (2007) How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther. 113 429-441. (Pubitemid 46149055)
7. Choudhuri, S., and Klaassen, C. D. (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259.
8. Ayesh, S., Shao, Y. M., and Stein, W. D. (1996) Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta 1316, 8-18.
9. Ferry, D. R., Russell, M. A., and Cullen, M. H. (1992) P-Glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site. Biochem. Biophys. Res. Commun. 188, 440-445.
10. Pascaud, C., Garrigos, M., and Orlowski, S. (1998) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem. J. 333 (part 2), 351-358. (Pubitemid 28379536)
11. Shapiro, A. B., and Ling, V. (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250, 130-137.
12. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006) Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J. 396, 537-545. (Pubitemid 44228168)
13. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006) Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem. J. 399, 351-359. (Pubitemid 44570297)
14. Pleban, K., Kopp, S., Csaszar, E., Peer, M., Hrebicek, T., Rizzi, A., Ecker, G. F., and Chiba, P. (2005) P-Glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: A combined photoaffinity labeling-protein homology modeling approach. Mol. Pharmacol. 67, 365-374.
15. Rothnie, A., Storm, J., Campbell, J., Linton, K. J., Kerr, I. D., and Callaghan, R. (2004) The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein. J. Biol. Chem. 279, 34913-34921.
16. Rosenberg, M. F., Kamis, A. B., Callaghan, R., Higgins, C. F., and Ford, R. C. (2003) Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J. Biol. Chem. 278, 8294-8299
17. Mechetner, E. B., Schott, B., Morse, B. S., Stein, W. D., Druley, T., Davis, K. A., Tsuruo, T., and Roninson, I. B. (1997) P-Glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. U.S.A. 94, 12908-12913
18. Nagy, H., Goda, K., Arceci, R., Cianfriglia, M., Mechetner, E., and Szabo, G. Jr. (2001) P-Glycoprotein conformational changes detected by antibody competition. Eur. J. Biochem. 268, 2416-2420
19. Julien, M., and Gros, P. (2000) Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity. Biochemistry 39, 4559-4568. (Pubitemid 30212673)
20. Loo, T. W., and Clarke, D. M. (1996) Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem. 271, 27482-27487
21. Loo, T. W., and Clarke, D. M. (1997) Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J. Biol. Chem. 272, 20986-20989.
22. Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., and Callaghan, R. (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128, 403-411.
23. Martin, C., Higgins, C. F., and Callaghan, R. (2001) The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 40, 15733-15742. (Pubitemid 34015202)
24. Rosenberg, M. F., Velarde, G., Ford, R. C., Martin, C., Berridge, G., Kerr, I. D., Callaghan, R., Schmidlin, A., Wooding, C., Linton, K. J., and Higgins, C. F. (2001) Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J. 20, 5615-5625. (Pubitemid 33010039)
25. Callaghan, R., Ford, R. C., and Kerr, I. D. (2006) The translocation mechanism of P-glycoprotein. FEBS Lett. 580, 1056-1063.
26. Liu, C. E., and Ames, G. F. (1997) Characterization of transport through the periplasmic histidine permease using proteoliposomes reconstituted by dialysis. J. Biol. Chem. 272, 859-866.
27. Tombline, G., Bartholomew, L. A., Urbatsch, I. L., and Senior, A. E. (2004) Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. J. Biol. Chem. 279, 31212-31220.
28. Dawson, R. J., and Locher, K. P. (2006) Structure of a bacterial multidrug ABC transporter. Nature 443, 180-185. (Pubitemid 44387602)
29. Loo, T. W., and Clarke, D. M. (1993) Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 268, 19965-19972.
30. Devine, S. E., Ling, V., and Melera, P. W. (1992) Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein altermultidrug resistance. Proc.Natl. Acad. Sci.U.S.A. 89, 4564-4568.
31. Song, J., and Melera, P. W. (2001) Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis. Cancer Chemother. Pharmacol. 48, 339-346.
32. Ecker, G. F., Csaszar, E., Kopp, S., Plagens, B., Holzer, W., Ernst, W., and Chiba, P. (2002) Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Mol. Pharmacol. 61, 637-648.
33. Greenberger, L. M. (1993) Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J. Biol. Chem. 268, 11417-11425.
34. Loo, T. W., and Clarke, D. M. (1994) Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33, 14049-14057 (Pubitemid 24382347)
35. Loo, T. W., and Clarke, D. M. (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J. Biol. Chem. 276, 14972-14979 (Pubitemid 37373379)
36. Zhang, X., Collins, K. I., and Greenberger, L. M. (1995) Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J. Biol. Chem. 270, 5441-5448
37. Storm, J., Modok, S., O'Mara, M. L., Tieleman, D. P., Kerr, I. D., and Callaghan, R. (2008) Cytosolic region ofTM6in P-glycoprotein: Topographical analysis and functional perturbation by site directed labeling. Biochemistry 47, 3615-3624.
38. Storm, J., O'Mara, M. L., Crowley, E. H., Peall, J., Tieleman, D. P., Kerr, I. D., and Callaghan, R. (2007) Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein. Biochemistry 46, 9899-9910. (Pubitemid 47378580)
39. Taylor, A. M., Storm, J., Soceneantu, L., Linton, K. J., Gabriel, M., Martin, C., Woodhouse, J., Blott, E., Higgins, C. F., and Callaghan, R. (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wildtype protein. Br. J. Pharmacol. 134, 1609-1618.
40. Hoedemaeker, F. J., Signorelli, T., Johns, K., Kuntz, D. A., and Rose, D. R. (1997) A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219. Design, expression, and crystal structure at 2.4 A ° resolution. J. Biol. Chem. 272, 29784-29789.
41. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
42. Chifflet, S., Torriglia, A., Chiesa, R., and Tolosa, S. (1988) A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: Application to lens ATPases. Anal. Biochem. 168, 1-4.
43. Martin, C., Berridge, G., Higgins, C. F., and Callaghan, R. (1997) The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br. J. Pharmacol. 122, 765-771.
44. O'Mara, M. L., and Tieleman, D. P. (2007) P-glycoprotein models of the apo andATP-bound states based on homology with Sav1866 and MalK. FEBS Lett. 581, 4217-4222. (Pubitemid 47301854)
45. Guex, N., and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714-2723. (Pubitemid 28059943)
46. Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., and Chang, G. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722.
47. Loo, T. W., and Clarke, D. M. (1997) Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J. Biol. Chem. 272, 31945-31948.
48. Berridge, G., Walker, J. A., Callaghan, R., and Kerr, I. D. (2003) The nucleotide-binding domains of P-glycoprotein. Functional symmetry in the isolated domain demonstrated by N-ethylmaleimide labelling. Eur. J. Biochem. 270, 1483-1492.
49. Davidson, A. L., and Nikaido, H. (1991) Purification and characterization of the membrane-associated components of the maltose transport system from Escherichia coli. J. Biol. Chem. 266, 8946-8951.
50. Ko, Y. H., and Pedersen, P. L. (1995) The first nucleotide binding fold of the cystic fibrosis transmembrane conductance regulator can function as an active ATPase. J. Biol. Chem. 270, 22093-22096.
51. Nikaido, K., Liu, P. Q., and Ames, G. F. (1997) Purification and characterization of HisP, the ATP-binding subunit of a traffic ATPase (ABC transporter), the histidine permease of Salmonella typhimurium. Solubility, dimerization, and ATPase activity. J. Biol. Chem. 272, 27745-27752.
52. Sonveaux, N., Vigano, C., Shapiro, A. B., Ling, V., and Ruysschaert, J. M. (1999) Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis. J. Biol. Chem. 274, 17649-17654.
53. Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., and Callaghan, R. (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624-632.